Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Corrado Pelaia, Anna Ferrante Bannera, Fioramante Lello Rotundo, Francesco Giuseppe Tropea, Giuseppe Armentaro, Angelantonio Maglio, Angela Sciacqua, Alessandro Vatrella & Girolamo Pelaia. (2023) Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 995-1002.
Read now
Read now
Ravi Kalhan, David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean Dale MacKnight & Beth Hahn. (2021) Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1149-1161.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Antonio Molino, Giovanna Calabrese & Mauro Maniscalco. (2018) Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Preference and Adherence 12, pages 993-1001.
Read now
Read now
Mohamed Ismail Abdul Aziz, Ling Eng Tan, David Bin-Chia Wu, Fiona Pearce, Gerald Seng Wee Chua, Liang Lin, Ping-Tee Tan & Kwong Ng. (2018) Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3203-3231.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Fulvio Braido, Mario Cazzola, Enrico Clini, Girolamo Pelaia, Andrea Rossi, Nicola Scichilone & Fabiano Di Marco. (2018) LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3115-3130.
Read now
Read now
Mike Thomas, David MG Halpin & Marc Miravitlles. (2017) When is dual bronchodilation indicated in COPD?. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2291-2305.
Read now
Read now
Articles from other publishers (21)
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran & Beth Hahn. (2021) Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D. MacKnight & Beth Hahn. (2021) Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary Therapy 7:1, pages 203-219.
Crossref
Crossref
M. Zysman, B. Ribeiro Baptista, T. Soumagne, V. Marques da Silva, C. Martin, C. Thibault de Menonville, L. Boyer, B. Degano, C. Morelot Panzini, P.R. Burgel, T. Perez, A. Bourdin, C. Raherison, H. Pégliasco, D. Piperno, C. Zanetti, H. Morel, B. Delclaux, C. Delafosse, A. Lorenzo, B. Housset, F. Chabot, P. Devillier, G. Deslée & N. Roche. (2021) Optimisation du traitement médicamenteux des patients atteints de BPCO en état stable. Position de la Société de pneumologie de langue française. Actualisation 2021. Revue des Maladies Respiratoires 38:5, pages 539-561.
Crossref
Crossref
Melissa Lipari, Pramodini B. Kale-Pradhan & Sheila M. Wilhelm. (2020) Dual– Versus Mono–Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis. Annals of Pharmacotherapy 54:12, pages 1232-1242.
Crossref
Crossref
Manoj J. Mammen, Vandana Pai, Shawn D. Aaron, Linda Nici, Waleed Alhazzani & Paul E. Alexander. (2020) Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. Annals of the American Thoracic Society 17:9, pages 1133-1143.
Crossref
Crossref
Linda Nici, Manoj J. Mammen, Edward Charbek, Paul E. Alexander, David H. Au, Cynthia M. Boyd, Gerard J. Criner, Gavin C. Donaldson, Michael Dreher, Vincent S. Fan, Andrea S. Gershon, MeiLan K. Han, Jerry A. Krishnan, Fernando J. Martinez, Paula M. Meek, Michael Morgan, Michael I. Polkey, Milo A. Puhan, Mohsen Sadatsafavi, Don D. Sin, George R. Washko, Jadwiga A. Wedzicha & Shawn D. Aaron. (2020) Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine 201:9, pages e56-e69.
Crossref
Crossref
Claire Ambery, Graeme Young, Teresa Fuller, Alex Georgiou, David Ramsay, Adeep Puri & Peter Daley‐Yates. (2018) Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently. Clinical Pharmacology in Drug Development 8:2, pages 188-197.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Ali Abdolahinia, Mohsen Naseri, Alireza Eslaminejad, Farzaneh Ghaffari & Aliakbar Velayati. (2018) Effect of Nepeta bracteata Benth. on Chronic Obstructive Pulmonary Disease: A Triple-Blinded, Randomized Clinical Trial. Iranian Red Crescent Medical Journal 20:12.
Crossref
Crossref
Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray & Richard H. Stanford. (2018) The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río & N. A. Risebrough. (2018) Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research 19:1.
Crossref
Crossref
Jose Luis Lopez-Campos, Laura Carrasco Hernández, Xavier Muñoz, Víctor Bustamante & Esther Barreiro. (2018) Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology 23:9, pages 818-827.
Crossref
Crossref
MeiLan K. Han, Riju Ray, Jason Foo, Chaienna Morel & Beth Hahn. (2018) Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD. npj Primary Care Respiratory Medicine 28:1.
Crossref
Crossref
Beth Hahn, Michael Hull, Cori Blauer-Peterson, Ami R. Buikema, Riju Ray & Richard H. Stanford. (2018) Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respiratory Medicine 139, pages 65-71.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Mohamed Bayoumi-Ali, Richard John Sweeney, Luqman Hussain Wali, Doaa Farag & Favas Thaivalappil. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
217
227
.
Maggie Tabberer, David A. Lomas, Ruby Birk, Noushin Brealey, Chang-Qing Zhu, Steve Pascoe, Nicholas Locantore & David A. Lipson. (2018) Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Advances in Therapy 35:1, pages 56-71.
Crossref
Crossref
Theresa N. Duong, Amir A. Zeki & Samuel Louie. (2017) Medical Management of Hospitalized Patients with Asthma or Chronic Obstructive Pulmonary Disease. Hospital Medicine Clinics 6:4, pages 437-455.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref